StemCell Therapy

Lately, there has been rising awareness among people regarding the therapeutic potential of stem cells for disease management. This is one of the key factors contributing to growth of the global stem cell therapy market.

Further, identification of new stem cell lines, research and development of genome based cell analysis techniques, and investment inflow for processing and banking of stem cell are some of the significant factors augmenting expansion rate of the global stem cell therapy market.

Meanwhile, limitations associated with traditional organ transplantation such as immunosuppression risk, infection risk, and low acceptance rate of organ by body are few features leading to adoption of stem cell therapy. Moreover, high dependency on organ donors for organ transplantation is paving opportunities for growth of the stem cell therapy.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1787

Moreover, expanding pipeline and development of drugs for new applications are driving growth of the global stem cells market. Growing research activities focused on augmenting the application array of stem cell will also widen the horizon of stem cell market. Researchers are consistently trying to develop novel methods for creating human stem cell in order to comply with the rising demand for stem cell production to be used for disease management.

Development of Advanced Treatment Method Augmenting Market Growth

Lately, various new studies, development of novel therapies, and research projects have come into light in the global stem cell therapy market. Some of these treatment have been by approved by regulatory bodies, while others are still in pipeline for approval of the treatment.

In March 2017, Belgian based biotech firm TiGenix has announced that its latest development- cardiac cell therapy AlloCSC-01 has reached in its phase I/II successfully. It has shown positive results. Meanwhile, the U.S. FDA has also approved the treatment method. If this therapy is well-accepted among the patients, then approximately 1.9 million AMI patients could be treated using the therapy.

Likewise, another significant development that has been witnessed is development novel stem cell based technology for treatment of multiple sclerosis (MS) and similar concerns associated with nervous system. The treatment is developed by Israel-based Kadimastem Ltd. Also, the Latest development has been granted a patent by reputed regulatory body.

Buy this Premium Report @ https://www.tmrresearch.com/checkout?rep_id=1787&ltype=S

Some of the prominent companies operating in the global stem cell therapy landscape are Anterogen Co. Ltd., RTI Surgical, Osiris Therapeutics Inc., Holostem Terapie Avanzate S.r.l., JCR Pharmaceuticals Co. Ltd., MEDIPOST Co. Ltd., Pharmicell Co. Ltd., and NuVasive Inc.

Some of these firms are following various growth strategies such as mergers and acquisitions, strategic alliances, and collaborations, and product development in order to strengthen their foothold in the global market for stem cell therapy.

Dermatology Segment Holds Prominence in Stem Cell Therapy Market

Stem cell therapy, primarily is a regenerative medicine. It encourages the reparative response of damaged, dysfunctional, or diseases tissue with the help of stem cells and associated derivatives. The treatment method is replacing the conventional transplant methods.

Stem cell therapy method has wide array of application in the field of nervous system treatment, dermatology, bone marrow transplant, multiple sclerosis, osteoarthritis, hearing loss treatment, cerebral palsy, and heart failure. The method aids patients fight leukemia and similar blood related diseases.

Among all, dermatology segment is leading in the global stem cell therapy market. The segment is substantially contributing to growth of the market. Stem cell therapy reduces the after effects of general treatment for burns such as adhesion, infections, and scars among others.

Get Table of Content of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1787

Meanwhile, rising number of patient suffering from diabetes and increase in trauma surgery cases are anticipated to accelerate the adoption of stem cell therapy in the dermatology segment.

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:TMR Research,3739 Balboa St # 1097,San Francisco, CA 94121United StatesTel: +1-415-520-1050Visit Site: https://www.tmrresearch.com/

Visit link:
Stem Cell Therapy Market Grows on Back of Growing Awareness Regarding Regenerative Treatment Methods - BioSpace

The global Musculoskeletal Disorder Stem Cell Therapy market study presents an all in all compilation of the historical, current and future outlook of the market as well as the factors responsible for such a growth. With SWOT analysis, the business study highlights the strengths, weaknesses, opportunities and threats of each Musculoskeletal Disorder Stem Cell Therapy market player in a comprehensive way. Further, the Musculoskeletal Disorder Stem Cell Therapy market report emphasizes the adoption pattern of the Musculoskeletal Disorder Stem Cell Therapy across various industries.

The Musculoskeletal Disorder Stem Cell Therapy market report examines the operating pattern of each player new product launches, partnerships, and acquisitions has been examined in detail.

The report on the Musculoskeletal Disorder Stem Cell Therapy market provides a birds eye view of the current proceeding within the Musculoskeletal Disorder Stem Cell Therapy market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Musculoskeletal Disorder Stem Cell Therapy market and offers a clear assessment of the projected market fluctuations during the forecast period.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2692084&source=atm

segment by Type, the product can be split intoAllogeneicAutologousMarket segment by Application, split intoMuscle diseaseSkeletal disease

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global Musculoskeletal Disorder Stem Cell Therapy status, future forecast, growth opportunity, key market and key players.To present the Musculoskeletal Disorder Stem Cell Therapy development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Musculoskeletal Disorder Stem Cell Therapy are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2692084&source=atm

The Musculoskeletal Disorder Stem Cell Therapy market report offers a plethora of insights which include:

The Musculoskeletal Disorder Stem Cell Therapy market report answers important questions which include:

The Musculoskeletal Disorder Stem Cell Therapy market report considers the following years to predict the market growth:

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2692084&licType=S&source=atm

Why Choose Musculoskeletal Disorder Stem Cell Therapy Market Report?

Musculoskeletal Disorder Stem Cell Therapy Market Reportfollows a multi- disciplinary approach to extract information about various industries. Our analysts perform thorough primary and secondary research to gather data associated with the market. With modern industrial and digitalization tools, we provide avant-garde business ideas to our clients. We address clients living in across parts of the world with our 24/7 service availability.

See the original post:
COVID-19: Potential impact on Musculoskeletal Disorder Stem Cell Therapy Market Estimated to Record Highest CAGR by 2019-2025 - Personal Injury Bureau...

Latest Study on Growth of Global Stem Cell Manufacturing Market 2020-2027. A detailed study accumulated to offer Latest insights about acute features of the Stem Cell Manufacturing market. This Report studies the latest industry trends, market development aspects, market gains, and industry scenario during the forecast period. The report provides the details related to fundamental overview, development status, latest advancements, market dominance and market dynamics. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market. It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary and SWOT analysis. This Stem Cell Manufacturing Industry report is consist of the worlds crucial region market share, size, trends including the product profit, price, value, production capacity, capability utilization, supply and demand and industry growth rate.

Stem cell manufacturing is forecasted to grow at CAGR of 6.42% to an anticipated value of USD 18.59 billion by 2027 with factors like rising awareness towards diseases like cancer, degenerative disorders and hematopoietic disorders is driving the growth of the market in the forecast period of 2020-2027.

Download Exclusive Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this [emailprotected]https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-stem-cell-manufacturing-market&AB

Stem cell manufacturing has shown an exceptional penetration in North America due to increasing research in stem cell. Increasing research and development activities in biotechnology and pharmaceutical sector is creating opportunity for the stem cell manufacturing market.

The Global Stem Cell Manufacturing Market 2020 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Stem Cell Manufacturing Market Share analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed.

Global Stem Cell Manufacturing Market Segematation By Product (Stem Cell Line, Instruments, Culture Media, Consumables), Application (Research Applications, Clinical Applications, Cell and Tissue Banking), End Users (Hospitals and Surgical Centers, Pharmaceutical and Biotechnology Companies, Clinics, Community Healthcare, Others)

List of TOP KEY PLAYERS in Stem Cell Manufacturing Market Report are

Thermo Fisher ScientificMerck KGaABDJCR Pharmaceuticals Co., LtdOrganogenesis IncOsirisVericel CorporationAbbVie IncAM-Pharma B.VANTEROGEN.CO.,LTDAstellas Pharma IncBristol-Myers Squibb CompanyFUJIFILM Cellular Dynamics, IncRHEACELL GmbH & Co. KGTakeda Pharmaceutical Company LimitedTeva Pharmaceutical Industries LtdViaCyte,IncVistaGen Therapeutics IncGlaxoSmithKline plc..

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart)@https://www.databridgemarketresearch.com/toc/?dbmr=global-stem-cell-manufacturing-market&AB

The report can help to understand the market and strategize for business expansion accordingly. In the strategy analysis, it gives insights from marketing channel and market positioning to potential growth strategies, providing in-depth analysis for new entrants or exists competitors in the Stem Cell Manufacturing industry. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. For each manufacturer covered, this report analyzes their Stem Cell Manufacturing manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The Global Stem Cell Manufacturing Market Trends, development and marketing channels are analysed. Finally, the feasibility of new investment projects is assessed and overall research conclusions offered.

Global Stem Cell Manufacturing Market Scope and Market Size

Stem cell manufacturing market is segmented on the basis of product, application and end users. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Based on product, the stem cell manufacturing market is segmented into stem cell lines, instruments, culture media and consumables. Stem cell lines are further segmented into induced pluripotent stem cells, embryonic stem cells, multipotent adult progenitor stem cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells. Instrument is further segmented into bioreactors and incubators, cell sorters and other instruments.

On the basis of application, the stem cell manufacturing market is segmented into research applications, clinical applications and cell and tissue banking. Research applications are further segmented into drug discovery and development and life science research. Clinical applications are further segmented into allogenic stem cell and autologous stem cell therapy.

On the basis of end users, the stem cell manufacturing market is segmented into hospitals and surgical centers, pharmaceutical and biotechnology companies, research institutes and academic institutes, community healthcare, cell banks and tissue banks and others.

Healthcare Infrastructure growth Installed base and New Technology Penetration

Stem cell manufacturing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for stem cell manufacturing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the stem cell manufacturing market. The data is available for historic period 2010 to 2018.

The Global Stem Cell Manufacturing Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of stem cell manufacturing market for global, Europe, North America, Asia Pacific and South America.

Key Insights in the report:

Historical and current market size and projection up to 2025

Market trends impacting the growth of the global taste modulators market

Analyze and forecast the taste modulators market on the basis of, application and type.

Trends of key regional and country-level markets for processes, derivative, and applicationCompany profiling of key players which includes business operations, product and services, geographic presence, recent developments and key financial analysis

For More Information or Query or Customization Before Buying, Visit @https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-stem-cell-manufacturing-market&AB

Opportunities in the market

To describe and forecast the market, in terms of value, for various segments, by region North America, Europe, Asia Pacific (APAC), and Rest of the World (RoW)

The key findings and recommendations highlight crucial progressive industry trends in the Stem Cell manufacturing Market, thereby allowing players to develop effective long term strategies

To strategically profile key players and comprehensively analyze their market position in terms of ranking and core competencies, and detail the competitive landscape for market leadersExtensive analysis of the key segments of the industry helps in understanding the trends in types of point of care test across Europe.

To get a comprehensive overview of the Stem Cell manufacturing market.

With tables and figures helping analyses worldwide Global Stem Cell Manufacturing Market Forecast this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.There are 15 Chapters to display the Stem Cell Manufacturing market.

Chapter 1, About Executive Summary to describe Definition, Specifications and Classification of Stem Cell Manufacturing market, By Product Type, by application, by end users and regions.

Chapter 2, objective of the study.

Chapter 3, to display Research methodology and techniques.

Chapter 4 and 5, to show the Stem Cell Manufacturing Market Analysis, segmentation analysis, characteristics;

Chapter 6 and 7, to show Five forces (bargaining Power of buyers/suppliers), Threats to new entrants and market condition;

Chapter 8 and 9, to show analysis by regional segmentation[North America, Europe, Asia-Pacific etc ], comparison, leading countries and opportunities; Regional Marketing Type Analysis, Supply Chain Analysis

Chapter 10, to identify major decision framework accumulated through Industry experts and strategic decision makers;

Chapter 11 and 12, Stem Cell Manufacturing Market Trend Analysis, Drivers, Challenges by consumer behavior, Marketing Channels

Chapter 13 and 14, about vendor landscape (classification and Market Ranking)

Chapter 15, deals with Stem Cell Manufacturing Market sales channel, distributors, Research Findings and Conclusion, appendix and data source.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia or Oceania [Australia and New Zealand]

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Our Upcoming Event:Future of Healthcare Robotics|Digital Conference

HEALTHCARE ROBOTICSis the upcoming future of Medical Sciences. The usage of robotics is already prevalent in surgeries across developed and emerging geographies. It has been quite a while where integration of robotics across healthcare supply chain is being discussed. The Covid 19 Pandemic is expected to speed up the timeline for these innovations and concepts to become reality. With the requirement of telemedicine and robotics in handling samples the healthcare industry is expected to see a digital paradigm shift in the next 2 years. The point here to be discussed is where the future is for healthcare robotics Surgical, Diagnostics or Telemedicine.

REGISTER NOW FOR FREE@https://www.databridgemarketresearch.com/digital-conference/future-of-healthcare-robotics?AB

In the pioneer edition of DBMR Healthcare Robotics Conference come join us in this enriching knowledge fest where experts will speak on new technologies and market dynamics perceptions. Together lets move ahead in the future of medical science and technology.

Read the original here:
Stem Cell Manufacturing Market Share, Size, Trends 2020- Segments worth Observing Aiding Growth Factors | Merck Group, Becton, Dickinson And Company....

Escaz is situated along the slopes of Cerro Escaz and is considered one of the most trendy and upscale suburbs of the San Jos metropolitan area. The city is located 7.5 miles (12 km) from San Jos and is a great place to enjoy the same amenities of the larger, busier city, but with a more relaxing feel. In Escaz, you can enjoy the unique atmosphere of Costa Rica with all the modern amenities you could want at your fingertips.

In town, there is a wide variety of little shops, boutiques, cafs, and restaurants. Some popular US chain restaurants are also available dining options. This is also home to the countrys largest shopping center, Multiplaza, a two-story mall located within minutes of the Stemedix offered hotels. This is where you can check out the latest fashion, watch a movie, or just walk around the enormous commercial center. Explore the culture of Costa Rica with nearby museums, National Theater, and architectural and historical landmarks. More adventure awaits with available tours, mountain view dining, and waterfall excursions.

See the article here:
Stem Cell Therapy in San Jose, Costa Rica - Stemedix ...

This Exosome Therapeutic Market business research report gives analysis and data according to categories such as market segments, regions, types, technology, end-user, applications and so on. The report offers the current industry data and upcoming trends of the industry, allowing the recognition of the products and end users boosting revenue growth and profitability. Moreover, this Exosome Therapeutic Market analysis document is structured with different graphical representations like graphs, charts, figures and diagrams with the specific arrangement of vital outlines, strategic diagrams, and illustrative figures based on reliable information to depict a correct picture of value judgement and income graphs.

Get Sample PDF (including COVID19 Impact Analysis) of Market Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&rp

Market Analysis and Insights:Global Exosome Therapeutic Market

Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

The major players covered in the Exosome Therapeutic Market report are evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global. Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Get Full TOC, Tables and Figures of Market Report @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&rp

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Exosome Therapeutic Market Scope and Market Size

Global exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process. The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

Rising demand of exosome therapeutic across the globe as exosome therapeutic is expected to be one of the most prominent therapies for autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases treatment, according to clinical researches exosomes help to processes regulation within the body during treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases. This factor has increased the research activities in exosome therapeutic development around the world for exosome therapeutic. Hence, this factor is leading the clinician and researches to shift towards exosome therapeutic. In the current scenario the exosome therapeutic are highly used in treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases and as anti-aging therapy as it Exosomes has proliferation of fibroblast cells which is significant in maintenance of skin elasticity and strength.

Based on source, the market is segmented into dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, urine and others. Mesenchymal stem cells are dominating in the market because mesenchymal stem cells (MSCs) are self-renewable, multipotent, easily manageable and customarily stretchy in vitro with exceptional genomic stability. Mesenchymal stem cells have a high capacity for genetic manipulation in vitro and also have good potential to produce. It is widely used in treatment of inflammatory and degenerative disease offspring cells encompassing the transgene after transplantation.

Based on therapy, the market is segmented into immunotherapy, gene therapy and chemotherapy. Chemotherapy is dominating in the market because chemotherapy is basically used in treatment of cancer which is major public health issues. The multidrug resistance (MDR) proteins and various tumors associated exosomes such as miRNA and IncRNA are include in in chemotherapy associated resistance.

Based on transporting capacity, the market is segmented into bio macromolecules and small molecules. Bio macromolecules are dominating in the market because bio macromolecules transmit particular biomolecular information and are basically investigated for their delicate properties such as biomarker source and delivery system.

Based on application, the market is segmented into oncology, neurology, metabolic disorders, cardiac disorders, blood disorders, inflammatory disorders, gynecology disorders, organ transplantation and others. Oncology segment is dominating in the market due to rising incidence of various cancers such as lung cancer, breast cancer, leukemia, skin cancer, lymphoma. As per the National Cancer Institute, in 2018 around 1,735,350 new cases of cancer was diagnosed in the U.S. As per the American Cancer Society Inc in 2019 approximately 268,600 new cases of breast cancer diagnosed in the U.S.

Based on route of administration, the market is segmented into oral and parenteral. Parenteral route is dominating in the market because it provides low drug concentration, free from first fast metabolism, low toxicity as compared to oral route as well as it is suitable in unconscious patients, complicated to swallow drug etc.

The exosome therapeutic market, by end user, is segmented into hospitals, diagnostic centers and research & academic institutes. Hospitals are dominating in the market because hospitals provide better treatment facilities and skilled staff as well as treatment available at affordable cost in government hospitals.

Exosome therapeutic Market Country Level Analysis

The global exosome therapeutic market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.

The countries covered in the exosome therapeutic market report are U.S. and Mexico in North America, Turkey in Europe, South Korea, Australia, Hong Kong in the Asia-Pacific, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua, Uruguay as part of Latin America.

Country Level Analysis, By Type

North America dominates the exosome therapeutic market as the U.S. is leader in exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

Competitive Landscape and Exosome Therapeutic Market Share Analysis

Global exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global exosome therapeutic market.

Many joint ventures and developments are also initiated by the companies worldwide which are also accelerating the global exosome therapeutic market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.

Customization Available:Global Exosome Therapeutic Market

Data Bridge Market Researchis a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&rp

About Data Bridge Market Research :

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us :

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:Corporatesales@databridgemarketresearch.com

More:
Exosome Therapeutic Market 2020 Major Growing Factors and Top Driving Force with Leading Players evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE...

Legal Issues in Stem Cell Therapy in the U.S.Jul 30, 2019 | Fred Greguras

My wife has had osteoarthritis, sometimes called wear-and-tear arthritis, in both of her knees since 2011. She first saw an advertisement for stem cell treatment in 2012 and continued to do research on the treatment. Late in 2018, after ultrasounds on her knees and consultation with several doctors and clinics in California and Colorado, she decided to have stem cell therapy that could regenerate the meniscus cartilage of her knees. Such therapy is a minimally invasive procedure that has the potential to slow the progress of the arthritic damage, repair joint cartilage and avoid or delay invasive knee replacement surgery. Such therapy can help the body repair itself naturally.

We thought it was best to act now before her knees worsened since the earlier the stem cell treatment began, the greater the chances for a successful outcome there would be. The present lack of health insurance coverage was considered, but the treatment cost was reasonable given the potential to avoid more invasive surgery and the timing of treatment. Most insurance plans, including Medicare, define the procedure as experimental and investigational and do not cover the therapy.

Based on her research, my wife selected Dr. Jason Glowney of Boulder Biologics to perform the treatment. Her treatment took place in the second week of January, 2019, as an outpatient at a hospital in Boulder, Colorado. The procedure was completed in under four hours. She was injected with her own stem cells (called an autologous donation), reducing the risk of immune rejection and other complications.

The medical team used ultrasound to identify the best sites for injection into the damaged tissue of her knees. The same needle remained in each knee site during the treatment, but the injections in each step described below were all done with separate syringes in sequence. There was no mixture of any of the multiple components in a single syringe.

The doctor gave her light oral sedation to help her relax for the procedure and used local anesthetic at the points of cell harvest and injection. No general anesthetic was administered. The procedure began with a harvest of platelet-rich plasma (PRP) from her blood. Her blood was quickly processed through a centrifuge to separate the blood and concentrate the platelets in the plasma, which was then injected to fertilize the knee sites to enhance cell growth. The concentrated platelets contain growth factors along with bioactive proteins that help initiate and stimulate tissue repair and regeneration. (In late May, 2019, she had another PRP injection to stimulate and enhance the growth of the stem cells.)

The next step in the procedure was to harvest her bone marrow, centrifuge it into an injectable volume of aspirate concentrate and then inject the concentrate in both knees. The bone marrow aspirate contains stem cells that can help regenerate bone and cartilage.

The adipose (fat-derived) stem cells used in the next step compliment the bone marrow stem cells. The adipose cells were harvested by a minimally invasive liposuction procedure, centrifuged to isolate the cells and then injected in both knees. The fat on our bodies can be a rich source of stem cells.

Hundreds of thousands of cells were harvested and injected in each step in order to have an adequate number of stem cells for the treatment. The stem cells decide whether to differentiate into bone, meniscus or other cartilage or to simply renew.

My wife was given antibiotic (doxycycline) tablets to take at the end of the procedure and, for a period thereafter, to assist the differentiation process and to help decrease cartilage degradation.

As discussed in more detail below, the doctors procedure was designed to involve only simple human cellular and tissue products from the same patient and not to be a new biological product or drug which requires FDA approval. The procedure would be a new biological product or drug requiring FDA approval if there had been more than minimal manipulation of each component part. Even a mixture of a patients own stem cells and an antibiotic administered from the same syringe would be deemed a new biological product or drug by the FDA.

The doctor gave my wife guidelines for physical activity and medications during the post-injection period. The guidelines were designed to promote the growth of the stem cells to regenerate tissue. The cells are fragile, and she had to be careful not to cause too much stress or shearing on them which could impede growth. Her pain was intense during the first 24 hours, and she stayed in bed much of the time. She used a walker for about the first week. She started physical therapy about six days after the injections with the doctors approval. The doctor recommended that she not take any anti-inflammatory medications (like ibuprofen or motrin), for six weeks since they could impede the differentiation of the stem cells. The doctor advised her that most patients dont feel any knee improvement for at least three weeks and possibly for up to six to eight weeks. If there is no improvement by the six-month point after the injections, then the therapy has not worked.

A self-reporting instrument is used for assessing a patients knee status. The 33 items measured are intended to represent all major indicators of knee status. My wifes measures are all very positive at this six-month point after the procedure. The measurement factors include: (1) knee symptoms such as knee swelling, stiffness and frequency of pain; (2) amount of pain in activities such as walking, standing and going up and down stairs; and (3) degree of difficulty in activities such as walking, bending down and going up and down stairs. Each item is rated on a five-point scale relating to the extent of its occurrence or severity during the past week.

Stem Cell Background

Stem cells are different from other cell types in our bodies because they are capable of renewing (copying) themselves through cell division, sometimes after long periods of inactivity. Stem cells also have the potential to differentiate into other cell types in our body. When a stem cell divides, each new cell has the potential either to remain a stem cell or to differentiate into more specialized cells that form the bodys tissues and organs. In some organs, stem cells regularly divide to repair and replace worn out or damaged tissues. In other organs, stem cells only divide under special conditions.

There are several types of stem cells that are formed at different times in our lives or come from different places in our body. Embryonic stem cells (ESCs) exist in the embryo only at the earliest stages of human development. ESCs are pluripotent, meaning they have the potential to differentiate into almost all cell types in the body. There are social and ethical issues relating to the use of ESCs, since harvesting the cells causes the destruction of an embryo. Many countries, including the U.S., have government-imposed restrictions on either ESC research or the production of new ESC lines.

Somatic or adult non-embryonic tissue-specific stem cells (ASCs) exist in specific tissues throughout the body after early human development. The stem cells injected into my wifes knees were ASCs. ASCs are multipotent, meaning they can differentiate into more than one type of specialized cell of the body, but not all types. ASCs are generally limited to differentiating into cell types of their tissue of origin, which can help with the replacement of cells from damaged tissue. ASCs can be an autologous stem cell donation, which is less likely to be rejected.

Amniotic stem cells (AMSCs) exist in the amniotic sac, which surrounds a baby in the uterus and remains until the babys birth. AMSCs are harvested right after the mother gives birth, without harming the baby. Some clinics make exaggerated claims about the therapeutic potential of ASMCs. AMSCs, however, are also multipotent, and the tissues they can differentiate into are substantially the same as stem cells from adipose (fat) and bone marrow. AMSCs exist only for a limited time, but adipose and bone marrow ASCs continue to be produced throughout our lives and can be harvested from the patient seeking therapy.

Some tissues and organs contain small amounts of ASCs whose function is to replace cells from that same tissue that deteriorate over time or are damaged by injury. For example, blood-forming stem cells in bone marrow can differentiate into red blood cells, white blood cells and platelets. However, blood-forming stem cells dont generate liver or lung or brain cells, and stem cells in other tissues and organs dont generate red or white blood cells or platelets.

Pluripotent stem cells have great therapeutic potential but still have major technical issues. Scientists cant control their differentiation into the many types of cells in the body which can result in unwanted tissue such as tumors. Since such stem cells are not from the recipient, they may also lack the compatibility needed to prevent rejection by the immune system.

Over 10 years ago, researchers identified conditions that enabled some specialized ASCs to be reprogrammed genetically back to an ESC-like state. The reprogrammed cells function similarly to ESCs and are called induced pluripotent stem cells (iPSCs). The iPSCs function similarly to ESCs, with the ability to differentiate into almost any cell of the body and to create an unlimited source of cells. iPSCs may ultimately help address the ethical concerns of ESCs and provide new potential for therapy, but there are still technical issues including whether they are actually equivalent to ESCs and the capability to control the differentiation process.

Legal Issues

FDA Approval Requirements

While the U.S. Food and Drug Administration (FDA) moves agonizingly slowly, its priority is human safety which is not the case in many other countries. Some other countries are the Wild West of stem cell therapy and have become medical tourism destinations for high-risk stem cell treatment. The FDA recommends that stem cell therapy is either FDA-approved or is done pursuant to an Investigational New Drug Application (IND), a clinical investigation plan submitted to and permitted to proceed by the FDA. There are many active clinical trials investigating the potential of ASCs listed on the U.S. National Institutes of Healths website.[1] Stem cell products approved by the FDA are listed on its web site.[2] There is no FDA-approved therapy involving the transplantation of ESCs. ESCs must be not be added to an injection, such as PRP, before it goes into a human.

The FDA regulates human tissues intended for transplant under 21 C.F.R. Part 1271: Human Cells, Tissues and Cellular and Tissue-Based Products (HCT/Ps). Cellular and tissue-based therapies are regulated by the Office of Cellular, Tissue and Gene Therapies within the FDA Center for Biologics Evaluation. There are two primary regulatory pathways for these products. Cellular therapy products that meet all the criteria in 21 CFR 1271.10(a) are regulated solely as HCT/Ps and are not required to be licensed, approved or cleared by the FDA. These products are often referred to as 361 products because they are regulated solely under Section 361 of the Public Health Service Act (PHSA).[3] The regulatory purpose for such products is to prevent the introduction, transmission and spread of communicable diseases.

If a cellular therapy product does not meet all the criteria in 21 CFR 1271.10(a), it is regulated as a drug, device and/or biological product under the Federal Food, Drug and Cosmetic Act (FDCA)[4] and Section 351 of the PHSA (a 351 product). The FDA requires premarket approval for such a product. The criteria that determine whether a product is a Section 361 HCT/P or a Section 351 biological product include, primarily, whether a product has been minimally manipulated and is intended for homologous use. Stem cell therapies generally do not satisfy these criteria and therefore are usually regulated as Section 351 products.

In the 2014 decision, United States of America v. Regenerative Sciences, LLC,[5] the court held that a mixture of autologous ASCs and other components was a 351 product and subject to FDA approval. Regenerative Sciences, LLC argued that its process did not create a mixture but only expanded the patients own cells and, therefore, was a simple 361 product which does not require FDA approval. The FDAs position is that any process involving human cellular and tissue products that includes culturing, expansion and added growth components or antibiotics requires FDA approval as a biological product or new drug because the process constitutes significant manipulation.

The FDA alleged that the product was a 351 product for failure to comply with its minimal manipulation provisions and because the resulting stem cells were not intended for homologous use. Homologous use means that a human cellular or tissue product is used clinically in a manner that is essentially the same as the natural function. The homologous use definition is strictly interpreted by the FDA, so that most innovative ways to use stem cells to potentially treat patients would be through non-homologous usage. The FDA will generally define even modestly different uses as non-homologous.

There are many clinics offering stem cell therapy in the U.S., some which carefully follow the law and others which do not. The FDA has only has brought a small number of enforcement actions because of resource limitations and proof concerns. Enforcement usually occurs in high-profile situations where a patient has died or is severely harmed.

Intellectual Property Issues

The two important types of intellectual property protection relating to stem cell therapy are trade secret and patent protection. For example, the cell harvesting techniques and settings for the centrifuge processing in each step in my wifes treatment can be protected as trade secret know-how. The culturing and cocktails of growth factors and/or other components in the Regenerative Sciences, LLC case are another example.

There are many patents registered with the USPTO that contain the term stem cell, but recently, many human stem-based inventions have been rejected for not being eligible patentable subject matter. Patent-eligible subject matter is defined in 35 U.S.C. Section 101 as: Whoever invents or discovers any new and useful process, machine, manufacture or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. There are three exceptions to subject matter eligibility: laws of nature, physical phenomena and abstract ideas.[6] The laws of nature exception has been the basis for rejection of patent eligibility for certain stem cell-related inventions.

There were two important court decisions in 1977 and 1980 relating to patent protection eligibility for the biotechnology industry.[7] The USPTO issued many stem cell patents following these decisions.

Several Supreme Court decisions in the past 10 years, however, have narrowed the scope of patent-eligible subject matter under Section 101.[8] In the Mayo decision, the Court held the invention was not patentable, stating that it effectively claimed the underlying laws of nature. The Court held that a claim that encompasses the use of a natural law must also include additional elements, sometimes referred to as an inventive concept, sufficient to ensure that the patent amounts to significantly more than a patent upon the natural law itself.

The scope of patent-eligible subject matter was further narrowed in the Myriad decision, which held that a naturally occurring DNA segment is a product of nature and not eligible for patent protection merely because it had been isolated. The Court looked for markedly different characteristics from any found in nature of the isolated gene to determine patent eligibility. The changes resulting from isolation of a gene sequence were considered incidental and not enough to make the isolated gene markedly different.

Three recent decisions in the Federal Circuit indicate that method-of-treatment claims that may involve a law of nature are patent-eligible.[9] Each of the patents required an affirmative treatment step. The decisions seem to hold that a patent directed to detecting a condition in a patient is not Section 101-eligible under Mayo, while a patent directed to using that detection to change some aspect of the patient is eligible. The patent may have been based upon the inventors discovery of a law of nature but the patent did not simply claim that law of nature. Rather, it was directed to a specific method of treatment.

The United States Patent and Trademark Office (USPTO) has published guidelines for patent examiners on how to analyze a claim which includes a nature-based product for patent eligibility.[10] Claims are to be examined for an inventiveness that has markedly different characteristics from naturally occurring products. Patent eligibility for a natural product is to be determined primarily by whether the claimed product possesses any structural, functional and/or other properties that represent markedly different characteristics from the natural counterpart. If the claim includes a nature-based product that has markedly different characteristics, then the claim is not within the product of nature exception. On the other hand, if the claim includes a nature-based product that does not have markedly different characteristics from its naturally occurring counterpart in its natural state, then the claim is within the product of nature exception and is not eligible for patent protection.[11]

The first step in the analysis is to select the counterpart(s) to compare to the nature-based product. The second step is to identify characteristics to compare, since the analysis is based on comparing the characteristics of the claimed nature-based product and its counterpart. Characteristics can be expressed as the nature-based products structure, function and/or other properties, and are evaluated on a case-by-case basis. The final step is to compare the characteristics of the claimed nature-based product to the characteristics of its naturally occurring counterpart in its natural state to determine if the characteristics of the claimed product are markedly different. If there is a change in at least one characteristic resulting from, or produced by, the patent applicants efforts or influences, then the change will generally be found to be a markedly different characteristic.

Consumer Protection

My wife was provided with disclosures from the doctors office and requested to sign a number of consents and waivers as a condition of receiving therapy. One of the waivers was a no assurance of successful treatment agreement.

State laws protecting consumers against deceptive advertising are applicable to representations about the effectiveness of stem cell treatment. Several state legislatures have debated additional protections for consumers relating to such treatment. California enacted a consumer protection law in late 2017 that requires clinics offering stem cell treatments to disclose if the treatment is not approved by the FDA.

The Federal Trade Commission (FTC) and FDA are pursuing enforcement actions in selected cases that may cause stem cell clinics to be more careful about their representations and activity. In late 2018, the FTC settled charges with a California-based physician and his businesses of deceptively advertising that amniotic stem cell therapy can treat serious diseases.[12] The settlement prohibits the defendants from making any health claims in the future unless the claims are true and supported by competent and reliable scientific evidence. This was the first enforcement action brought by the FTC against a stem cell clinic.

In early June, 2019, a federal judge granted the FDA an injunction to prevent the U.S. Stem Cell Clinic (based in Florida) from offering treatments using adipose stem cells injected into the spinal cords of patients to treat Parkinsons disease, chronic obstructive pulmonary disease and other serious conditions.[13] The court held that the defendants misbranded the possible therapeutic effects. The court also determined the clinic failed to prevent microbiological contamination of products which put patients at risk for infections.

Conclusion

As indicated, the status measures for my wifes knees are all very positive six months after the procedure. She is glad she tried it. I would try the therapy if I have problems with my knees.

The FDA will continue to move slowly to approve stem cell therapies since its priority is human safety. Some other countries have become medical tourism destinations for high-risk stem cell treatment. Many of the claims of such foreign clinics and of some clinics in the U.S. are medically unproven. The FDA and other regulators will continue to bring enforcement actions based on the severity of patient risk and available resources. Obtaining patent protection for stem cell-related inventions is challenging because of the subject matter eligibility issue under Section 101. The recent method-of-treatment decisions in the Federal Circuit may provide a helpful eligibility precedent for some inventions.

Read the original:
Legal Issues in Stem Cell Therapy in the U.S. - Inventus Law

Welcome to the Institute of Ophthalmology and Visual Science. The Institute's ophthalmic surgeons are members of University Hospital's medical staff. They are dedicated to providing outstanding, compassionate patient care. Because the physicians work in close physical proximity, patients are readily afforded consultation from our many ophthalmic subspecialists. The Institute features state-of-the-art diagnostic equipment (housed in the Ocular Imaging Center and in the Ophthalmic Electrodiagnostic Laboratory) and offers the most advanced therapies available.

The Institute is the only one in New Jersey that provides 24-hour coverage for every disease and/or condition of the eye. Our highly skilled, dedicated team has the expertise to treat even the most complex cases, no matter when a problem occurs.

Our physicians are also active researchers, who are continually searching for new ways to diagnose and treat eye diseases and, perhaps, one day help people to regain their sight. We are involved in clinical trials so patients have access to cutting-edge technology that may not be available elsewhere for years.

The Institute offers diagnosis and medical and surgical treatments for cornea and external ocular diseases, glaucoma and retinal diseases/disorders. Our team also has experts in pediatric ophthalmology; neuro-ophthamology; oculoplastic and reconstructive surgery; orbital surgery, and low vision optometric and rehabilitative care.

SPECIALIZED SERVICES INCLUDE:

MEET OUR TEAM OF SPECIALISTS

Marco A. Zarbin, MD, PhD, Chair

Larry P. Frohman, MD, Vice Chair

Neelakshi Bhagat, MD, MPH

Peter S. Hersh, MD,

Monique S. Roy, MD

Rudolph S. Wagner, MD

David S. Chu, MD

Suqin Guo, MD,

Paul D. Langer, MD

Roger E. Turbin, MD

Amir Cohen, MD, MBA,

Mohammad H. Dastjerdi, MD

Albert S. Khouri, MD

Ronald J. Rescigno, MD

Saysha M. Blazier, OD

TO CONTACT US FOR AN APPOINTMENT:

Institute of Ophthalmology and Visual ScienceDoctor's Office Center, Suite 610090 Bergen StreetNewark, NJ 07103973-972-2020

DEPARTMENT ADMINISTRATIVE CONTACT:

Barbara ChurchillPhone: 973-972-2038Email: chucrchbf@rutgers.edu

Go here to see the original:
Ophthalmology | Specialized Services | University Hospital ...

A new study was presented by Adroit Market Research offering a complete analysis of the Opthalmology Pacs Market where the user can benefit from the complete market research report with all the useful information required on this market. This is a final report, covering the current impact of COVID-19 on the market. The coronavirus pandemic (COVID-19) has affected all aspects of life around the world. This has resulted in several changes in market conditions. The rapidly changing market scenario and the initial and future impact assessment are addressed in the report. The report examines all major aspects of the market with expert opinion on the current state of the market as well as historical data. This Opthalmology Pacs market report is a detailed study of growth, investment opportunities, market statistics, analysis of growing competition, key players, industry facts, important figures, sales, prices, revenues, gross margins, market shares, business strategies, main regions, demand and developments.

Top Leading Key Players are:

Topcon Corporation, IBM corporation, Carl Zeiss Meditec AG, EyePACS, Heidelberg Engineering and more.

Get Sample Copy of this Report: https://www.adroitmarketresearch.com/contacts/request-sample/608

Opthalmology Pacs market largely focuses on prominent facets such as product portfolio, payment channels, service offerings, applications, in addition to technological sophistication. This comprehensive research- documentary on global Opthalmology Pacs market is a holistic perspective of market developments, factors, dynamics, trends and challenges that decide growth trajectory of global Opthalmology Pacs market. The report lends versatile cues on market size and growth traits, besides also offering an in-depth section on opportunity mapping as well as barrier analysis, thus encouraging report readers to incur growth in global Opthalmology Pacs market.

The Opthalmology Pacs Market Report provides a detailed analysis of the global market size, regional and national market size, segment growth, market share, competitive landscape, sales analysis, the impact of players in national and global markets, value chain optimization, business regulations, recent developments, opportunity analysis, strategic analysis of market growth, product launches and technological innovations.

Browse the complete report @ https://www.adroitmarketresearch.com/industry-reports/opthalmology-pacs-market

Global Opthalmology Pacs market is segmented based by type, application and region.

Based on Type, the market has been segmented into:

By End-Use, market is segmented into:

HospitalsAmbulatory Surgical Center (ASCS) & Specialty ClinicsOthersBy Type, market is segmented into:

Standalone PACSIntegrated PACSBy Delivery Model, market is segmented into:

Cloud/ web based modelsOn-premise modelsOthers

Every year the prediction period is precisely considered in terms of worth and production in the global as well as regional markets respectively. Moreover, the Opthalmology Pacs market report has been consistently studied with respect to the significant market segments. Technical growth aspects of the global Opthalmology Pacs market have been studied by majorly focusing on the number of technical platforms, methodologies, and tools. In addition to this, the research report on Opthalmology Pacs market offers a detailed overview of the business strategies of the major service providers and the new market entering across the globe are analysed in the report. Moreover, this research report give a better understanding of the SWOT analysis, contact information as well as revenue share are also profiled in this report.

This Opthalmology Pacs market has been divided into types, applications and regions. The growth of each segment provides a precise calculation and forecast of sales by type and application, in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting qualified niche markets. Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, Asia-Pacific, the Middle East and Africa and Latin America. Research analysts understand competitive forces and provide competitive analysis for each competitor separately.

For Any Query on the Opthalmology Pacs Market: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/608

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

Read the original post:
Opthalmology Pacs Market 2020, by Services, Company Profiling, Business Revenue, and Growth Opportunities to 2025 - Cole of Duty

Active Pharmaceutical Ingredients (API) market size was valued at USD 179.77 billion in 2018 and is projected to reach to USD XX billion by 2026 at a CAGR of XX %.

This is a comprehensive global report focused on the current and future prospects of the active pharmaceutical ingredients market. This report is a consolidation of primary and secondary research, which provides market size, share, dynamics, and forecast for various segments and sub-segments considering the macro and microenvironmental factors. An in-depth analysis of past trends, future trends, demographics, and technological advancements for the active pharmaceutical ingredients market has been done in order to calculate the growth rates for each segment and sub-segments.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/1816

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

An active pharmaceutical ingredient is a biologically active portion of a pharmaceutical drug intended to perform certain pharmacological actions or have prominent effects for the diagnosis, cure, treatment or prevention of chronic and acute diseases.

The rising prevalence of chronic diseases and increasing uptake of biopharmaceuticals is expected to majorly drive the market growth.

As per data published by the World Health Organization (WHO), chronic disease prevalence is anticipated to rise by 57.0% by the year 2020. The number of people suffering from diabetes in developing countries was 84.0 million in 1995, which is projected to increase by 2.5-fold to 228.0 million in 2025. Chronic diseases include diabetes, obesity, and cardiovascular diseases, cancer, neurological diseases, and other diseases; the rise in prevalence of these diseases are augmenting the demand for treatment that may support the market growth over the forecast period.

Furthermore, augmented demand for rapid-acting & efficient drugs and the emergence of innovative drug manufacturing facilities are expected to assist in market growth during the forecast period.

Loss of drug exclusivity is impeding the revenue growth!

Patent expiration is accountable for the huge loss for pharmaceutical firms in terms of revenue, which is anticipated to impede the market growth during the forecast period.

The biotech APIs segment is expected to witness significant market growth.

The biotech APIs segment is expected to register comparatively higher CAGR over thee forecast period owing to high R&D for novel biosimilar drugs, escalating demand for protein-based therapeutics, and rising key traditional manufacturers focus toward biological drugs.

The branded/innovative drugs segment spearheaded the market.

A surge in prescription rates and drug prices coupled with higher spending on R&D activities are expected to contribute to the dominance of the branded/innovative drugs segment.

The merchant manufacturers segment is expected to witness lucrative market growth.

Worldwide rising outsourcing of API/drug molecule formulation from drug manufacturers in order to eliminate the need for heavy investment in manufacturing processes.

North America is expected to hold a major chunk of the market during the forecast period.

North America is anticipated to hold substantial market share over next ten years owing to the presence of favorable government initiatives, changing lifestyle leads to the development of diseases, rising investment on R&D, and technological developments in drug manufacturing processes.

Key Highlights:

Active pharmaceutical ingredients market size analysis and forecast Comprehensive study and analysis of market drivers, restraints, and opportunities influencing the growth of the active pharmaceutical ingredients market Active pharmaceutical ingredients market segmentation on the basis of synthesis type, drug type, manufacturer type, therapeutic area, and geography (regional) Active pharmaceutical ingredients market strategic analysis with respect to individual growth trends, future prospects along with a contribution of various sub-market stakeholders have been considered under the scope of a study Active pharmaceutical ingredients market analysis and forecast for five major regions such as North America, Europe, Asia Pacific, Latin America, and MEA. Profiling of key industry players, their strategic perspective, market positioning and analysis of core competencies Competitive landscape of the key players operating in the active pharmaceutical ingredients market including competitive developments, investments, and strategic expansion

Years that have been considered for the study are as follows:

Base Year 2018 Estimated Year 2019 Forecast Period 2019 to 2026

For company profiles, 2018 has been considered as the base year. In cases, wherein information was unavailable for the base year, the years prior to it have been considered.

Research Methodology:

The market is estimated by triangulation of data points obtained from various sources and feeding them into a simulation model created individually for each market. The data points are obtained from paid and unpaid sources along with paid primary interviews with key opinion leaders (KOLs) in the market. KOLs from both, demand and supply side were considered while conducting interviews to get an unbiased idea of the market. This exercise was done at a country level to get a fair idea of the market in countries considered for this study. Later this country-specific data was accumulated to come up with regional numbers and then arrive at the market value for active pharmaceutical ingredients market.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/1816

Some of the key players of the active pharmaceutical ingredients market include:

AbbVie Inc. Bristol-Myers Squibb Company Boehringer Ingelheim GmbH Cipla Inc. Merck & Co., Inc. Eli Lilly and Company Mylan N.V. Teva Active Pharmaceuticals Industries Ltd. Aurobindo Pharma Sun Pharmaceutical Industries, Ltd. Dr. Reddys Laboratories Ltd. Albemarle Corporation

Key Target Audience:

Healthcare companies Corporate healthcare entities Government agencies Market research and consulting firms Venture capitalists Technical StudentsScope of the Active Pharmaceutical Ingredients Market Report:

The research report segments the active pharmaceutical ingredients market based on synthesis type, drug type, manufacturer type, therapeutic area, and geography.Active Pharmaceutical Ingredients Market, By Synthesis Type

Biotech Monoclonal Antibodies Recombinant Proteins Vaccines SyntheticActive Pharmaceutical Ingredients Market, By Drug Type

Branded Drugs Generic Drugs Over-the-counter (OTC) DrugsActive Pharmaceutical Ingredients Market, By Manufacturer Type

Captive Manufacturers Merchant ManufacturersActive Pharmaceutical Ingredients Market, By Therapeutic Area

Cardiology Pulmonology Opthalmology Neurology Oncology Orthopedics OthersActive Pharmaceutical Ingredients Market, By Geography

North America U.S. Canada Europe UK Germany France Italy Spain Rest of Europe Asia Pacific Japan China India Rest of Asia Pacific Latin America Brazil Mexico Rest of Latin America MEA South Africa Saudi Arabia Rest of MEA

MAJOR TOC OF THE REPORT

Chapter One: Active Pharmaceutical Ingredients (API) Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Active Pharmaceutical Ingredients (API) Market Competition, by Players

Chapter Four: Global Active Pharmaceutical Ingredients (API) Market Size by Regions

Chapter Five: North America Active Pharmaceutical Ingredients (API) Revenue by Countries

Chapter Six: Europe Active Pharmaceutical Ingredients (API) Revenue by Countries

Chapter Seven: Asia-Pacific Active Pharmaceutical Ingredients (API) Revenue by Countries

Chapter Eight: South America Active Pharmaceutical Ingredients (API) Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Active Pharmaceutical Ingredients (API) by Countries

Chapter Ten: Global Active Pharmaceutical Ingredients (API) Market Segment by Type

Chapter Eleven: Global Active Pharmaceutical Ingredients (API) Market Segment by Application

Chapter Twelve: Global Active Pharmaceutical Ingredients (API) Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Active Pharmaceutical Ingredients (API) Market Report at:https://www.maximizemarketresearch.com/market-report/active-pharmaceutical-ingredients-api-market/1816/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

Continued here:
Active Pharmaceutical Ingredients (API) Market Industry Analysis and Forecast (2019-2026)_by Synthesis Type (Biotech, Synthetic), by Drug Type...

University of Otago researchers have discovered some of the secrets to longevity with new research revealing not smoking and being social engaged throughout older age are common traits of New Zealand centenarians.

Associate Professor Yoram Barak, a consultant psychogeriatrician, says the results show people can have some control over the ageing process.

Electing not to smoke and committing to maintain social networking will be the best investment one can make towards successful ageing, he says.

Being socially active means physically going out of your home and away from families and interacting with people whether that is visiting friends, volunteering or participating in activities such as attending a concert or playing golf, Professor Barak says.

Together with his colleague Professor Paul Glue, from the Department of Psychological Medicine, and Dr Sharon Leitch from the Department of General Practice and Rural Health, Associate Professor Barak set out to investigate the variables associated with exceptionally healthy extreme old age.

This is so we can make some recommendations to try and help people age well.

The researchers examined data relating to 292 centenarians who were free of common chronic diseases such as diabetes, depression, dementia and hypertension. They also included information relating to a further 103,377 older people aged over 60. All of these people were living in private accommodation in the community and not in aged residential care.

Results showed social engagement of participants, whereby they are participating in social activities of long-standing interest was similar across all age groups.

Rates of depression and diabetes declined steadily with increasing age and rates of dementia declined after the age of 80. Hypertension rates increased by nearly 30 per cent from age 60 to 100 years.

There is evidence that exercise improves health and length of life but in this study most participants had a similar profile of physical activity and there was not sufficient spread of duration or intensity of physical activities to test the effects on ageing.

However, among those surveyed the highest physical activity groups were at the lowest risk of dementia.

As of 2011, there are estimated to be between 400 to 500 centenarians living in New Zealand. Of these, fewer than 40 would be aged over 105. The mean age of those interviewed in the study was 101.

The centenarians were more likely to be female (75 per cent) and in any age group, women were more likely to be free of the common chronic diseases outlined above.

Women have a longer life expectancy and are therefore more likely to be represented in centenarian studies. However, after correcting for this advantage, men who do make it to 100 years of age are more likely to be free of common illnesses, Associate Professor Barak says.

This study found higher rates of centenarians free of common chronic diseases in New Zealand than reported in other countries.

However, one explanation is that this survey considered only centenarians living in the community, who were likely to be in better health compared with those living in residential care or hospital settings.

Professor Barak explains the biopsychosocial foundations of remarkable health and longevity among centenarians is unclear. Genetic factors, certain geographical locations and life-style characteristics have all been studied in an effort to identify potential predisposing factors of exceptional longevity.

The research was recently published in international scientific journal Aging Clinical and Experimental Research.

Visit link:
Not smoking and being socially active keys to longevity, Otago research shows - New Zealand Doctor Online

International Mens Health Week: Men may seem physically stronger than women, they are mentally weak. Also, most of them are extremely careless towards their health and ignore common signs that may be signals of a bigger health issue than they think. This negligence when mixed with the daily stress of work, family issue etc., can gradually lead to depression or any other ailment that can be quite debilitating. So, in order to live a happy, healthy, and longer life, they must bring some changes in their lifestyle. Here we tell you about those changes. Also Read - International Mens Health Week 2020: 4 Common Ailments That Are Prevalent in Men And Shouldn't be Ignored

Needless to say, smoking is known to cause both physical and mental damage. From damaging your lungs to causing heart diseases, and leading to behavioural issues, smoking is associated with an array of health ailments. Nicotine present in cigarettes may even cause uncontrolled growth of some cells in your lungs and cause cancer. Additionally, it can significantly lower your sperm count and affect your sex life.

A sedentary lifestyle is one of the major reasons behind a bulging belly and problems associated with it. Obesity can affect your cardiovascular health, impact your blood pressure, and increase your risk of suffering from a stroke. Thats why it is important to stay fit. For that, you need to exercise. If nothing, you can at least start jogging or cycling. These aerobic exercises can bring a big difference in your health.

Eating junk foods like burger, french fries etc. can increase the level of bad cholesterol in your blood and that can lead to a heart attack or stroke. Also, it can cause obesity which is again linked to diabetes, high blood pressure and many other ailments. So, men must include vitamins, carbohydrates, minerals, and protein in their daily diet. For that, they can have lentils, green leafy vegetables, fruits, eggs etc.

Continued here:
International Mens Health Week: All Men Must Make These Lifestyle Changes For Better Health And Longevity - India.com

People are now living longer worldwide while birth rates have declined well below replacement levels in the western world. This is widely interpreted in a negative light, and I have done so myself, but an article by Andrew Scott published by the World Economic Forum points out that when chronological age statistics (number of years one is alive) are converted to biological age (the health of your cells, or how old you really are) little or no increase in average real age can be discerned in most developed economies since the 1950s.

And another report by Mark Haas in The National Interest earlier this year claims ageing populations increase the likelihood of international peace. So, increased longevity offers unexpected dividends and public policy should be framed to harvest these dividends.

The UN estimates the share of population aged 60 years and over will increase in every country up to 2050. Life expectancy is growing fastest in emerging markets where the number of people aged 60 years and over is double that in the developed world. This ratio will increase to 4:1 by 2050.

Increased life expectancy and declining birth rates increase the average population age, eg in Japan median age rose from 26 years in 1952 to 46 years today. It is popularly argued that such ageing weakens economies because it increases the old-age dependency ratio (OADR), thereby slowing economic growth and putting pressure on public budgets. OADR is the proportion of the population over 64 years relative to the working age population (15 years to 64 years). The OADR concept assumes that older people are unproductive consumers of the government benefits generated by 15- to 64 year-olds.

As countries industrialise, birth rates decline, increasing the relative size of the elderly sector and one would expect average mortality to rise because mortality rates are higher for older people. However, while the average age in advanced economies has been increasing since 1950, average mortality rates have declined for all ages for several reasons medical advances, falling smoking rates etc. Chronological ageing is offset by a longevity effect. The average citizen has become chronologically older but biologically younger.

The conventional demographic time-bomb picture described previously makes no distinction between ageing and longevity effects and predicts a very negative picture of the future. The picture is much brighter when the longevity effect is factored in and would become even brighter if birth rates were restored to replacement levels in the western world in the near term.

In advanced economies today 75-year-olds have the same mortality rates as 65-year-olds in 1950. Scott reports that when changed mortality rates are used to adjust for age inflation in order to determine real average age, little or no increase in real age is seen in recent decades in the UK, Sweden, France, Germany and the US. Japan is an exception with an increase of average real age from 31 years to 44 years. This is attributed to the dramatic collapse of birth rates in Japan since the end of the second World War.

Of course, as Scott points out, while the average person now lives a longer healthier life this does not apply to everybody and significant differences can be discerned based on income, lifestyle, education, environment and genetics. And, so, public policies must be devised both to help those who still age in the traditional sense and to harness the dividends offered by the many older-but-productive citizens, facilitating them in full employment or offering more flexible working arrangements.

Huge monies are now expended on anti-ageing research and it may be possible to significantly extend the span of healthy living further by developing medicines that slow down ageing while boosting the bodys defences against diseases. Some geneticists predict that people may live to 150 years by 2100.

Increased likelihood of world peace is a further dividend offered by our ageing societies. The big fear in this context is of war between the superpowers US, Russia and China. Each power has a rapidly ageing population, particularly Russia and China. It is known that countries with a surplus of military-aged citizens (18-30 years) as a percentage of total population are more likely to engage in international hostilities than countries with older populations.

William Reville is an emeritus professor of biochemistry at UCC

View post:
Are societies really ageing? - The Irish Times

Every fall is not the same, but similar. It is a good time to pick up businesses having longevity, and ride through this volatility. But, investors cannot expect to reap benefits immediately as markets don't like uncertainty, Hemang Kapasi, Portfolio Manager Equity Investment Products, Sanctum Wealth Management, said in an interview with Moneycontrols Kshitij Anand.

Edited excerpt:

Q) Indian market snaped two-weeks of positive close and turned negative. What led to the fall on D-Street especially when it started off on a bullish note?

A) If one does an analysis of equity market performance for the last one month, all the major world equity market indices are in positive territory from ~5-15 percent.

Investors worldwide turned euphoric about the resumption of economic activities as lockdowns are being lifted across the world supported by stimulus packages by the governments and liquidity pumped in by the central banks.

Even Indian equity markets participated in this rally with gains of about ~11 percent in the last one month. Post a sharp up move in the equity markets world over, and just before the FOMC meeting, investors were seen booking profits ahead of an important event, and Indian equity markets were no exception.

A) Going forward, equity markets would be a function of economic recovery and sustained liquidity support provided by central banks to support financial markets.

As India is still coming out of lockdown and if one goes by forecasted negative GDP growth for the year, then we are likely to be trading on the higher range on indices.

A) Lockdown would not be a solution as the pandemic is here to stay for some time till the vaccine is found. Lockdown can be used to create health infrastructure, but it cant contain cases as seen in this lockdown.

Lockdown impacts the whole economy and impacts each and every one. Governments, Corporates, and individuals will have to work around this taking precautions and move ahead as economic implications are far more severe if lockdown is implemented

A) As a lender of last resort, theGovernment has to take measures to support the economy. To predict the manner in which it can be implemented is a futile exercise, governments have to step up to revive demand when the need arises.

A) With equity markets having a big up move in the last one month, there is some positivity seen in mid & small-cap space. Having said that they are still down 22 percent from their 1 year high and 32 percent down from their all-time high in December 2017

A) Financials are a place of uncertainty for the next 6 months. In the coming days they might be struggling on both topline and bottom-line.

Credit growth pick-up might take a bit of time to pick up as banks have become risk-averse to lending in these uncertain environments and on the other hand they will have to deal with rising NPAs related provisions.

Thats the reason the financial sector is among the worst-performing sector in the last 3 months, having said that any improvement in the above two-aspect will lead to huge re-rating for this sector.

A) Its true, history may not repeat but it does rhyme. Every fall is not the same but similar. It is a good time to pick up businesses having longevity and ride through this volatility. But, investors cannot expect to reap benefits immediately as markets don't like uncertainty.

Moneycontrol Ready Reckoner

Now that payment deadlines have been relaxed due to COVID-19, the Moneycontrol Ready Reckoner will help keep your date with insurance premiums, tax-saving investments and EMIs, among others.

Special Offer: Subscribe to Moneycontrol PRO at 1 per day for the first year. Coupon code: PRO365. Offer available on desktop & android only. *T&C Apply

Original post:
'Good time to invest in firms having longevity, but don't expect returns immediately' - Moneycontrol.com

Years ago sometimes it seems like eons ago I wrote a book and did a PBS special titled The Longevity Code: Your Personal Prescription for a Longer, Sweeter Life.

I learned a lot about writing a book. If youve never had this experience, let me clue you in its not that easy. When youre done, you realize you learned so much that youd like to change the whole thing and start over again.

The problem is you have the publishers deadline. Crown Publishing, an imprint of Random House, had its deadline for my book, so out the door it went.

In that book, I postulated there were five spheres that affect our wellness: physical, mental, family/social, spiritual and material. I thought and still do think these are ways you can organize your life space, learning what you need to do to improve your longevity, keep robust and healthy and avoid disease and disability.

Its kind of like buckling your seat belt. Taking action reduces risk but doesnt eliminate it.

I put physical first because I am first and foremost a doctor using science and medicine to guide my judgment but realizing they dont have all the answers. Some of those whether or not youre happy or sad, pleased with your life or not might not be up to science at all. Thats why life balance and the other four spheres are so important.

Now that were dealing with social distancing, I am starting to realize perhaps I have been wrong in my analysis the social sphere should come first.

When lecturing, I like to pepper my talk with stories and jokes. Thats the only way to keep an audience on task; anecdotes help us emote.

When I get to the social sphere, I often say, Why go to the gym to get the best body you can if you dont have someone to share it with? Its a cute, trite thing to say and usually gets a laugh.

But, truth be told, I see now with the latest isolation situations that we crave our social connections. Yes, we have phones, FaceTime, etc., but the lack of in-person contact comes with a cloud that seems to hang over all of us.

We want these connections with others more than ever now that we must keep them at a distance.

Getting together with friends and family, exchanging ideas and checking in with others are critical to our health. When I have patients who retire, I always ask them how its going. Often, they say they dont miss the job, but they do miss seeing their co-workers.

Social connectedness gives us pleasure, influences our health and motivates us to take action for ourselves and others.

A recent study of more than 300,000 people showed that a lack of strong social relationships could increase death by up to 50% which is about the same as smoking half a pack a day.

So why is this so important? Ive read about this for more than 20 years and have distilled what I think are the most salient points.

Being connected gives us joy and pleasure because we are incredibly social. In the book Sapiens: A Brief History of Humankind, by Yuval Noah Harari, the author postulates that the reason Homo sapiens took over from other humanoid species was our ability to form social relationships and engage in cooperative behavior.

My spin: During this time of physical distancing, its critical to use all the electronic tools we have to stay connected it benefits our health. As we come out of hibernation from winter and look to resume connecting in our usual physical way, we now need to take a little bit different action.

Handshakes, fist bumps and high fives will return. And those hugs from friends and family that make us feel so good will feel even better when we get to share them once again. Stay well.

View post:
Dr. Zorba Paster: Pandemic helps doctor realize our social spheres of prime importance to our health - The Spokesman-Review

Its an undeniable truth that aging is inevitable. Or is it? What if almost everything we have been taught about aging is wrong? What if we could change how long we live? In other words, could we choose our lifespan? David Sinclair, a Harvard professor, medical researcher and author of Lifespan, was recently a guest on the Aspen Brain Lab expert series. He explained to host Dr. Marc Hodosh why he believes we can really influence our longevity.

Sinclair explained that aging is a disease. Aging should be redefined as a medical condition and approached as a disease both causing fragility and often death.

The reality is aging is the root cause of most of the planets suffering and kills 100,000 people every day. Sinclair believes that when we come to this realization, then we will be able to address aging more productively.

The statistics show that the age of our community is rising, especially in the developed world. In 2017, one in eight people worldwide was aged 60 or over. In 2050, older people are projected to account for one in five people globally. So by 2050, this group will be around two billion.

An individuals lifespan is linked to lifestyle factors, more than genetics. In fact, science reveals that your lifespan will be determined by your lifestyle accounting for up to 70% Genetics will determine only 30%.

Sinclair told Hadosh that individual diseases occur in the minority, and aging to the majority. So why arent we taking aging far more seriously than we are currently? he questions.

He believes there is a need for more international attention to social, economic and political risks as well as the benefits of a world in which billions of people can live much longer and much healthier lives.

Sinclair explained that ones chronological age (the number of times weve travelled around the sun) is not the same as our biological age (how our cells have changed over that same period of time). He defines the nine different hallmarks of aging :

Like many other scientists involved in the study of aging, Sinclair believes we need to approach aging from a preventative health perspective over ones lifespan. This is a more cost-effective approach than addressing acute symptoms of the disease later on in life, he told Hadosh.

And hes pretty optimistic that science may soon have the tools to put this disease into remission.

During the discussion Sinclair spoke about the importance of hormesis and its role in lifespan and the aging process. The application of hormesis in aging research and interventions is becoming increasingly attractive and successful. The reason for this is that the research conducted over many years, is showing that mild stress-induced activation of one or more stress response (SR) pathways, and its consequent stimulation of repair mechanisms, is effective in reducing the age-related accumulation of molecular damage.

Hormesis is the what doesnt kill you makes you stronger type of stress. Stress is the disruption of homeostasis, or your bodys state of equilibrium. In fact, your body thrives on occasional stress or toxin exposure, and responds by ramping up growth and repair to bring you back to balance. Thats hormesis your bodys positive response to minor stressors. Over time, you can use hormesis to build an adaptive stress response, where you learn to benefit from sources of stress.

With exercise, for example, you need to exert your muscles, otherwise your body wont build them back stronger. Also your brain needs to be challenged. You can do this by learning a new language, or doing something creative. Its important to continually build new connections between brain cells. You can even stimulate new collagen growth in your skin with lasers and microneedling both of which cause micro-injuries. Sitting in a sauna, followed by a cold shower is also another simple way to practice hormesis.

Sinclair believes youthfulness can also be reset in the body using epigenetic reprogramming. Soon we will be able to tweak cells in a particular way that the central nervous system behaves as if it were young again.

The central nervous system is one of the first body tissues to lose regenerative capacity. His research group was able to show that the expression of 3 specific genes in mice was able to reset youthful gene expression patterns. Promoting regeneration following optic nerve crash injury also restored vision in a mouse model of glaucoma.

The group also concluded that old tissues retain a faithful record of youthful information that can be accessed for functional age reversal.

This is an exciting moment in time for the science of longevity. Researchers are on the verge of understanding the process of aging and how to create drugs that promote extended healthy longevity.

Some may argue that humans and mice are not the same, so we shouldnt get overly optimistic about these studies. However, without a doubt the work being done in their laboratory at Harvard Medical School is forward thinking and may well be lifechanging. As Sinclair attests, This is the golden era of genetics. Anything is possible. We are only limited by our imagination.

We took a look at how Sinclair is approaching his own lifespan? While hes written a lot on the subject, these 4 lifestyle interventions to improve the way we age offer a good summary from the scientist.

Sinclair says if there is one lesson weve learned this past decade it is this: aging is malleable. He has made certain changes in his own life to give himself a decent shot at having a long, healthy life.

We all need to be pushing ourselves, physically, especially as we get older and yet, Sinclair says, only 10 percent of people over the age of 65 do. The good news is that we dont have to exercise for hours on end. People who run four to five miles a week (for most people, thats an amount of exercise that can be done in less than 30 minutes every other day) reduce their chance of death from a heart attack by 40 percent and all-cause mortality by 45 percent. Thats a massive effect.

Youll know you are doing vigorous activity when it feels challenging. Your breathing should be deep and rapid, you should sweat and be unable to say more than a few words without pausing for breath. This is the hypoxic response, and its great for inducing just enough stress to activate your bodys defenses against aging without doing permanent harm.

David Sinclair believes theres nothing revolutionary about fasting. As far back as Hippocrates, the ancient Greek physician, doctors have been espousing the benefits of limiting what we eat. This is not the same thing as malnutrition. This is when the systems of our bodies begin to prey upon one another. But allowing our bodies to exist in a state of want is unquestionably good for our health and longevity.

Increasingly, research is showing through studies that reducing food availability over a lifetime has remarkable effects on aging and lifespan of animals, so most likely will on humans too.

Sinclair is a firm believer in the benefits of intermittent fasting, citing numerous studies pointing to the health benefits of intermittent fasting. In one such study, participants ate a normal diet most of the time, but five days a month ate a restricted diet. In three months, those who maintained the fasting mimicking diet lost weight, reduced their body fat and lowered their blood pressure, too. Participants also had lower levels of a hormone primarily made in the liver called insulin-like growth factor 1, or IGF-1. Mutations in the IGF-1 and IGF-1 receptor genes are associated with lower rates of death and disease.

So how does Sinclair do it? My blood sugar rises in the morning and I am not hungry. So I skip breakfast, except for two tablespoons of homemade yogurt. I try to skip lunch or eat a late lunch of a small soup or salad. At dinner I eat a normal dinner, with a focus on plant-based foods. I do not overeat. My downfall is alcohol. I often have a glass of wine for dinner a few times a week.

According to this aging specialist, the bottom line is that there is no best diet. What works for someone may not work for another. We are all different. With different ages, circadian rhythms, jobs, body compositions, microbiomes, stresses, and wants. No matter what you do, a little fasting goes a long way.

Even eating certain plants will make a difference, suggests Sinclair. Health-promoting molecules are produced in abundance by stressed plants. Sinclair explains that we get resveratrol from grapes, aspirin from willow bark, metformin from lilacs. We obtain epigallocatechin gallate from green tea, quercetin from fruits, and allicin from garlic.

This may be evidence of xenohormesisthe idea that plants respond to stress by producing chemicals that tell their cells to hunker down and survive.

In 2008, together with Konrad Howitz they penned the term xenohormesis Their theory is that animals evolved to sense certain chemicals in stressed plants as an early-warning system, of sorts. . Over the long-term, this provides humans with health and longevity. In the same way intermittent fasting and exercise are thought to. In fact, he says, they activate the same hormetic pathways.

Sinclair says we should be eating plants and foods raised under less-than-ideal conditions, organic, small farm-raised, or from our own backyard. When plants are stressed, they often add extra color to their stems or leaves.

For example, when a plant or a fruit is exposed to too much light, you may have noticed it produces extra red, blue or purple pigments. These are anthocyanins and they are produced not only by radiation damage, but drought, adverse temperatures, nutrient restriction, pathogens, and wounding. Xenohormetic molecules are typically produced alongside anthocyanidins. I look for leafy vegetables that are bright in color, not light green. I dont mind if they have holes eaten in them or are limp.

And if youre wondering which wine grapes have the highest resveratrol content? Sinclair says its pinot noir, because they are so stress-sensitive.

Sinclair suggests cold therapy is another way to better your lifespan chances. Cold therapy helps activate the mitochondria in your brown fat. He writes that his interest in the potential health benefits of cold therapy began in 2008 with a chance meeting at TEDMED with Ray Cronis former NASA scientist turned expert in nutrition and bioenergetics. The two began working together and they published a paper together with Andrew Bremmer at the NIH, titled The Metabolic Winter Hypothesis: A Cause of the Current Epidemics of Obesity and Cardiometabolic Disease.

Writes Sinclair: We propose that our 7-million-year evolutionary history, which was dominated by two seasonal challenges, lead to calorie scarcity and mild cold stress. But in the last 0.9 inches of our evolutionary mile, we solved them both. Put another way, we may be in evolutionary discordance between our biology that evolved to counter seasonal calorie scarcity and mild cold stress and our modern world of ubiquitous calories and excess warmth. Very few of us experience the outdoor cold of winter, and even fewer of us sleep at cool temperatures.

Yes, you guessed it. Sinclair takes a colder view of life. He leaves a window slightly open at night and avoids heavy blankets while he sleeps. He says he also turns the thermostat down to 67 at night. At the gym, he plunges into a cold pool up to his neck for at least 20 seconds. The scientist says doing this leaves him feeling refreshed and energized for the rest of the day. He expects his healthy brown fat to be turning even browner.

This is a controversial area for anyone in the scientific world to venture into. Perhaps more so for an academic specializing in aging. Realistically though, who wouldnt want to know what he is personally taking to age better? David Sinclair definitely looks a lot younger than his 51 years. According to multiple reports and broadcast material on the subject, he regularly tracks his biomarkers and takes vitamin D, vitamin K2, and aspirin.

Sinclair also uses three other longevity-specific substances each morning. These include resveratrol, NMN, and metformin, a diabetes drug currently being studied for its potential anti-aging effects. The researcher is always quick to point out to the media that hes not a medical doctor and that hes not recommending anyone do what he does. This is purely what he does personally, based on what he is learning.

While the natural human inclination is to seek the fountain of youth, theres never a shortage of naysayers. The stakes are particularly high in this area of health. David Sinclair may well be conducting his own real-time personal longevity experiment alongside his lab. However, whatever your viewpoint, I think we can all agree, the best advice is not to wait until the science is proven. You can already adopt many of these strategies without any risk. Be proactive about improving your lifespan now.

David A. Sinclair, Ph.D. A.O. is a professor in the Department of Genetics and co-director of the Paul F. Glenn Center for the Biology of Aging at Harvard Medical School. He obtained his Ph.D. in Molecular Genetics from the University of New South Wales, Sydney in 1995. Dr. Sinclair is co-founder of several biotechnology companies (Sirtris, Ovascience, Genocea, Cohbar, MetroBiotech, ArcBio, Liberty Biosecurity) and is on the boards of several others. He is also co-founder and co-chief editor of the journal Aging.

His work is featured in five books, two documentary movies, 60 Minutes, Morgan Freemans Through the Wormhole and other media. He is the inventor of 35 patents.

Sinclair and has received more than 25 awards and honors. These include the CSL Prize, The Australian Commonwealth Prize, Thompson Prize, Helen Hay Whitney Postdoctoral Award. As well as the Charles Hood Fellowship, Leukemia Society Fellowship, Ludwig Scholarship, Harvard-Armenise Fellowship, American Association for Aging Research Fellowship. Included are the Nathan Rodriguez Award from the National Institutes of Health, Ellison Medical Foundation Junior and Senior Scholar Awards. Merck Prize and the Genzyme Outstanding Achievement in Biomedical Science Award.

Sinclair was also awarded the Bio-Innovator Award, David Murdock-Dole Lectureship, Fisher Honorary Lectureship, Les Lazarus Lectureship and the Australian Medical Research Medal. His work has been recognized with The Frontiers in Aging and Regeneration Award, Top 100 Australian Innovators, and TIME magazines list of the 100 most influential people in the world.

David Sinclair is the author of the book Lifespan. A must-read for anyone interested in aging.

See more here:
Has Everything We've Been Taught About Aging Wrong? - Longevity LIVE

Randy Orton and Tommaso Ciampa got into a Twitter beef following NXT TakeOver: In Your House when Orton sent out a backhanded compliment about leg slaps.

Ciampa responded by saying he uses Orton matches to put his daughter to sleep and Orton noted that he seemed to upset one of the locker room leaders in NXT.

Speaking to CBS Sports, Orton clarified his "leg slap" comments and how he views NXT.

"So, the leg slap comment was just me having fun and it got taken a little too seriously," he noted before saying he's seen more leg slaps and repeated moves as so many wrestlers use a superkick or running knee.

"That has nothing to do with the state of Tommaso's physical wellbeing, but there's that style. If you're a talent and you've made it as far as NXT, which is very close to the top of the mountain ... if you think that you have to go out there and get powerbombed on the apron after neck surgery, or if you think you have to go out there and do these dives and flips bell to bell just because the fans want to see half a dozen near-death experiences? I feel sorry for you because you're not going to reap the benefits of what this business offers," said Orton. "One of those is longevity. I don't know anything about what NXT pay is like, but it certainly ain't Raw and SmackDown pay. I don't know what you get paid for a TakeOver, but I'm going to go out on a limb and guess that, at WrestleMania, my paycheck was bigger than the TakeOver guys. Now, I hate when guys talk about 'my big bank account' or 'my big check' or this or that and 'I'm more rich than you.' That's not what I'm saying here. I'm saying that NXT shouldn't be the goal. Raw or SmackDown should be the goal."

Orton went on to say that he wants Ciampa to have a long and healthy career where he can retire and not have to learn a new trade.

"I want to see all these guys succeed. When you're talking about that? Making money. It's a business. It's a business. You've got to make money. I would think, no matter how much you love NXT, you've got to look at the bigger picture. If you don't think you're going to last on the road for Raw and SmackDown? Do something about it. Go and sign a contract that calls for you to only show up at TV. They do NXT every week and they do a TakeOver whenever. They're wrestling about as much as we're wrestling, especially right now. With the future and no one knowing how many shows we're going to be putting on, I think it's a bit of a cop out to say, 'I can get four years of NXT versus one year of Raw or SmackDown,'" said Orton before noting that he would love to work with Ciampa and believes he's great at telling stories.

He continued, "All different kind of fans love all different kinds of styles and there's definitely a popular style down in NXT. I'm not saying fans are wrong and I'm not saying the wrestlers are wrong. I'm just saying there's no longevity in it. There's no chance you're going to be able to have a 10, 15, 20-year career and be able to support your family. If you have multiple kids, especially, there's no way to do that in NXT. That's why there's the major leagues and the major leagues are Raw and SmackDown. The major leagues are main eventing WrestleMania. Main eventing a TakeOver should be a huge notch on your belt. Winning the NXT championship should be a huge notch on your belt. But, I know when Kevin Owens won the NXT championship, he couldn't wait to get called up to the main roster because that dude is a bad motherf--ker and he can go. He wanted to show the world and he was going to reach more fans being on Raw, being on SmackDown, being in marquee matches in Madison Square Garden, being in WrestleMania on the Network. By doing that, he was going to be able to show how awesome of a talent he is."

Orton finished by saying NXT is one step away from the top and he doesn't want anyone to stop there.

As of now, Ciampa remains in NXT while Orton is one of the top stars on WWE Raw.

Continued here:
Randy Orton: Theres No Longevity In The NXT Style The Goal Should Be Raw Or SmackDown - Fightful

Saturday, June 13, 2020 4:00 AM

Dear Overseas Worker:To answer your second question first, n o, your benefit amounts will not change because you are married and both collecting. Based upon the numbers you provided, neither of you will be eligible for a spousal boost from the other because your benefit amounts at your FRA are too similar, so maximizing your individual benefits should be your goal.As for your other question, when you should start collecting depends upon a number of factors, including your financial needs and, importantly, your expected longevity. Both of you can get the maximum benefit available to you by waiting until you are 70 years old to claim, but that only makes sense if you are in good health and expect at least average longevity (about 84 for a man and 87 for a woman).If you claim benefits before you reach your full retirement age (66 for you and 66 plus 4 months for your husband), those benefits will be cut. If you collect now, your benefit would be cut by about 27% and your husbands by about 22% (based upon your respective years of birth). Further, if you claim before your full retirement ages and continue to work, youll be subject to Social Securitys earnings test, which limits the amount you can earn before they take back some of your benefits (the 2020 earnings limit is $18,240; if you exceed that theyll take back half of anything you earn over the limit). The earnings limit changes annually but goes away at your FRA.At your full retirement ages, youll be entitled to 100% of the benefits youve earned from your lifetime of working (approximately the amounts estimated now). If you can and do wait beyond your full retirement age (FRA), for each month you delay youll earn delayed retirement credits of 2/3 of 1% per month of delay (8% per year of delay), up to age 70 when your maximum benefit is reached. As a point of information, if you wait until your full retirement age to claim, you will have collected the same amount of money at age 78 as if you had claimed at age 62; and if you wait until age 70 to claim youll have collected the same amount of money at age 82 as if you had collected at your full retirement age. If you live at least until average longevity, youll collect more in cumulative Social Security benefits by waiting.So, when should you claim? If youre still working and earning professional salaries, then waiting at least until your full retirement age would be a wise choice. If you expect at least average longevity and dont need the money right away, waiting until age 70 would be a prudent strategy. But if you dont work and expect less than average longevity, then claiming at any time you need the money would be a reasonable decision. This is a choice only each of you can make.

By AMAC Certified Social Security Advisor Russell Gloor. This article is intended for information purposes only and does not represent legal or financial guidance. It presents the opinions and interpretations of the Association of Mature American Citizens Foundations staff, trained and accredited by the National Social Security Association.. NSSA and the AMAC Foundation and its staff are not affiliated with or endorsed by the Social Security Administration or any other governmental entity. To submit a question, visit our website (amacfoundation.org/programs/social-security-advisory) or email us atssadvisor@amacfoundation.org.

Submit a comment

2020 The Timesa division of Sagamore News Media54 N 9th Street, Noblesville, IN

(317) 770-7777

life

Software 1998-2020 1up! Software, All Rights Reserved

Read this article:
When should we claim our benefits? - The Times

In an industry flooded with content standing out from the crowd has arguably never been more crucial, but how is that achieved?Andy Sekula, head of games at Kalamba, believes that withmechanics and math originality you stand a fair chance of succeeding.

The theme and visuals of a slot game are what draws a player in, but its the mechanics that keeps them returning time and again. Innovations introduced in the last few years such as the Megaways engine have demonstrated how transformational a new feature can be for the whole gaming community particularly in an age of content overload where players are faced with myriad choice of games that barely differentiate.

For developers striving for originality, the race is now on between suppliers, both large and small, to create the next big feature that defines a new era. But that doesnt mean trying to reinvent the wheel every time.

Innovation in slot mechanics is a balancing act: introducing something that is too foreign can be off-putting to players, while leaning too heavily on proven successes means you fail at delivering something new.

The sweet spot lies in keeping with what is mostly familiar, improving on it, and introducing some novelty so that the gameplay feels fresh and exciting. And since its the games mechanics which define the math model and monetisation getting it right from the start can be the make or break of a games performance.

Fully understanding player preferences and behaviour is a fundamental component to the development of new features. It is important that studios make informed decisions based on objective evidence, rather than opinion keeping players top of mind from the early stages.

Creating that stickiness with players is an important part of ensuring a games success, longevity and profitability

When developers spend so much time with a game, it is easy to forget that players arecompletely new to it when released. A games creators therefore need to constantly consider how a player will interact with the slots features and mechanics, making sure they are easy to understand and, of course, add to the overall enjoyment.

Tracking engagement with previous releases provides a useful tool to gauge what works and what doesnt, offering a foundation of information on how features can be improved in future iterations.

At Kalamba, we look at the session lengths and number of rounds played to get an indication of the games instant performance, while the number of times a player returns determines whether the experience is appealing enough to come back to even after the games disappears from the lobby.

Creating that stickiness with players to which the mechanics are fundamental is an important part of ensuring a games success, longevity and profitability.

This performance data has been central to Kalambas design process and shaped thedirection of our portfolio in the last few years through feature enhancements. In the earlydays, we concentrated on high-volatility titles with complex mechanics that were targeted at slot enthusiasts.

While these performed well with the intended audience, with analysis of KPIs over time, combined with feedback from operators, we decided to switch tactics.

We now look at developing games with a lower base level but introducing customisable mechanics, such as our HyperBet feature, which allows players to increase the base bet amount of the game as well as the volatility, and HyperBonus, which provides a shortcut tothe bonus round.

It is only with new mechanics and math originality that new hits are created

By enabling players to adapt the gameplay to suit their preferred playstyle, weve broadened the appeal of portfolio, making our titles more accessible to casual players, whilst allowing those with more experience to increase the volatility to meet their risk appetite.

Using these innovations as a foundation for our game development, the Kalamba feature set has advanced dramatically, with new additions like LuckyLoops and progressive free spins moving the engagement dial even further.

The new LuckyLoops feature lets players accumulate special symbols on every base game spin and every tenth spin, the player is rewarded with a special spin, for example expanding accumulated symbols.

To complement our in-game concepts, we are also developing Bullseye, our promotional tools and social gaming inspired elements (think leaderboards and tournaments) that connect our portfolio.

In a content-flooded industry that is full of imitation and skins, it is only with new mechanics and math originality that new hits are created. And although not every feature iteration or new concept is going to be a winner, using data as a guide and of course, taking the occasional risk on an experiment you stand a fair chance of succeeding.

Read more from the original source:
Kalamba Games: Striving for mechanics that break the mould - Casino Beats

(Daniel Taylor - Kelowna Capital News)

Your morning start for Wednesday, June 17, 2020

Good morning, Okanagan! Happy hump day!

One study, conducted by a University of Sydney professor, titled Stairway to Hell: Life and Death in the Pop Music Industry, examined the deaths of artists which took place between 1950 and June 2014. The study specifically looked at longevity and the proportion of suicides, homicides, and accidental deaths. Longevity was determined by calculating the average age of death for each musician by sex and decade of their death. These averages were then compared with averages by sex and decade for the general U.S. population. The results? Musicians lifespans are 25 years shorter.

In Kelowna:

In Vernon:

In Penticton:

In Salmon Arm:

A South Okanagan massage therapist is no longer allowed to treat female patients after accusations he sexted during appointments and sneaked looks at patients naked bodies.

Last week, the College of Massage Therapists of British Columbia announced it launched an investigation into Brent Rowland, formerly of Naramatas now closed Equilibrium Massage Therapy.

A note posted to the Equilibrium Massage Therapy by Rowland, stated the practice is being suspended for the foreseeable future.

READ MORE: Central Okanagan teacher suspended for showing South Park, John Oliver to students

Daniel Taylor

Reporter, Kelowna Capital News

Environment Canada weather

Go here to see the original:
Morning Start: Musicians have shorter life spans than the general population - Vernon Morning Star

Retirement can be joyous and less expensive if we take care of ourselves

In a recent survey of more than 5,000 workers, ranging from millennial to baby boomer, conducted by the Transamerica Center for Retirement Studies, eight in 10 participants asserted that they are in excellent or good health.

Those self-assessments seem optimistic when viewed aside national health data:

According to the Centers for Disease Control and Prevention, some 40% of adults are obese.

High blood pressure is an issue for more than four in 10 adult Hispanic and white Americans, and nearly six in 10 non-Hispanic black Americans.

An estimated one in four Americans at least 65 years old is diabetic, with 90%-plus of those cases being Type 2 diabetes that can be moderated, if not eliminated, through dietary changes.

Yes, there is a much longer list of illness and disease absolutely out of ones personal control. But weight, blood pressure and Type 2 diabetes are often conditions that can be managed or moderated through the personal initiative of a healthier diet and (more) exercising. Quality sleep is another lever that can improve health and quality of life, now and down the line.

A visit with your primary care physician, during which you dont minimize your health concerns but seek strong advice on addressing them, is a good start to feeling better. Dont leave the doctors office without a plan.

Additional motivation can come from the financial implications of being in poor health. Medical bills are a leading cause of bankruptcy in the U.S., and a relatively healthy retirement is a lot cheaper to fund than one burdened by heavy drug costs, doctor visits and hospitalizations.

The nonpartisan Employee Benefit Research Institute takes a deep data dive each year to estimate the out-of-pocket medical expenses 65-year-olds might encounter over the rest of their lives. The estimate accounts for Medicare premiums, deductibles and co-payments, and prescription drug costs not covered by Medicare supplemental plans. It explicitly does not include the cost of long-term care.

If a 65-year-old couple today wants a high probability (90%) that they will have the funds to pay for all those medical costs through the rest of their lives, they are estimated to need a combined $325,000 if they end up with high prescription drug costs (again, the 90th percentile). If their drug costs are at the median they would need $270,000.

Yes, both estimates are eye-openers, but remember, this is for two people, and it is for total expenses in retirement. Given increased longevity of retirees,

there is a 50 percent probability someone in average health at 65 will still be alive in their mid-80s. So that total cost is spread out over plenty of years. But even so, the difference between typical and high drug costs adds up to a big chunk of retirement funds. To understand longevitys impact on your retirement planning, read this:https://www.rate.com/research/news/retirement-expectancy

Taking better care of yourself is a key retirement-planning strategy. And its one of the rare times where doing something for your future self also provides a payoff in the here and now. A healthier approachbe it physical or mental (ideally both)is bound to help you feel better today.

Consider a couple hacks:

Share your goal with someone, an exercise or diet buddy, and make plans to check in together regularly. Sounds simple, but so often we keep this sort of stuff to ourselves. Yet having an accountability friend has been shown to help people stick to goals.

Write a letter to your 65- or 75-year-old self, sharing what you hope to be doing then. An academic research project found that people who went through this exercise were more likely to keep going to a gym.

Write it down. A record of exercise, eating, weight and blood pressure can help connect your daily activities to your longer-term goals.

Visit link:
'Oh, I'm Fine' the Cost of Self-Deception About Health - Guaranteed Rate